Dry eye disease is a chronic condition caused by an unstable or insufficient tear film. It does not go away with occasional lubricating drops. Left unmanaged, it causes progressive surface damage, worsening discomfort, and, in some cases, permanent corneal scarring. Long-term management, not short-term relief, is the correct approach, says Dr Shibal Bhartiya.
Dry eye is one of the most common eye conditions seen in clinical practice. Most patients manage it with over-the-counter drops and expect it to resolve. It rarely does.
Dry eye disease is a multifactorial condition of the ocular surface. The tear film is complex. When it breaks down, the result is inflammation, epithelial damage, and a cycle that perpetuates itself without targeted treatment.
Understanding dry eye as a chronic disease changes how patients manage it, and how much vision and comfort they can preserve over time.
Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.
What Is Dry Eye Disease?
Dry eye disease (DED) is defined by the TFOS DEWS II report as a multifactorial disease of the ocular surface. It involves loss of tear film stability and is accompanied by symptoms and signs of varying severity.
The tear film has three layers: a mucin layer anchoring tears to the eye surface, an aqueous (watery) layer providing nutrients and oxygen, and a lipid (or oil) layer produced by the meibomian glands that prevents evaporation. A problem in any one layer causes disease.
Two Main Types of Dry Eye
Aqueous Deficient Dry Eye
This type involves insufficient tear production. The lacrimal gland does not produce enough aqueous fluid. It is common in post-menopausal women, patients with Sjogren’s syndrome, and those on antihistamines, antidepressants, or blood pressure medications.
Evaporative Dry Eye
This is the more common type, accounting for roughly 85 percent of all dry eye cases. Meibomian gland dysfunction (MGD) is the primary cause. Blocked or abnormal meibomian glands fail to secrete a healthy lipid layer, and tears evaporate too quickly.
Many patients have both types simultaneously. Treatment must address the dominant mechanism.
| Feature | Aqueous Deficient DED | Evaporative DED |
| Primary cause | Reduced lacrimal gland output | Meibomian gland dysfunction |
| Proportion of cases | Approximately 15% | Approximately 85% |
| Key risk factors | Sjogren’s, medications, age | Screen use, blepharitis, rosacea |
| Tear break-up time | Reduced | Very short (under 5 seconds) |
| Treatment focus | Tear supplementation | Lid hygiene, heat, omega-3 |
| Inflammation present | Often yes | Yes, secondary |
Why Dry Eye Becomes Chronic
The tear film and ocular surface exist in a feedback loop. When the tear film is unstable, the surface desiccates. This triggers inflammation. Inflammation damages goblet cells and lacrimal tissue. Damaged tissue produces less stable tears. The cycle continues.
Without breaking this cycle, not just lubricating the surface, dry eye worsens over months and years. This is why patients who only use drops often find their symptoms returning or intensifying.
Chronic untreated dry eye can cause corneal epithelial breakdown, punctate keratitis, subepithelial scarring, and, in severe cases, corneal ulcers. These are not trivial outcomes.
Risk Factors That Drive Progression
- Screen use of more than four hours daily reduces blink rate and increases evaporation.
- Contact lens wear disrupts the tear film and accelerates meibomian gland dropout.
- Hormonal changes — especially menopause — reduce lacrimal and meibomian secretions.
- Systemic medications including antihistamines, SSRIs, diuretics, and isotretinoin reduce tear production.
- Autoimmune conditions such as rheumatoid arthritis, lupus, and thyroid disease affect the lacrimal gland.
- Rosacea is a strong risk factor for meibomian gland dysfunction and is frequently undiagnosed.
- Air conditioning, low humidity, and air travel accelerate tear evaporation.
- Prior LASIK or refractive surgery causes corneal nerve damage and temporarily reduces reflex tearing.
How Dry Eye Is Diagnosed
Diagnosis requires more than a symptom questionnaire. A structured assessment includes the OSDI (Ocular Surface Disease Index) score, tear break-up time (TBUT), Schirmer’s test, corneal and conjunctival staining with fluorescein and lissamine green, and meibomian gland evaluation.
Meibography — infrared imaging of the meibomian glands — shows the degree of gland dropout and guides treatment intensity. Patients with significant gland loss need early and aggressive intervention to preserve remaining function.
Tear osmolarity testing measures the salt concentration of tears. Elevated osmolarity confirms tear film instability and is useful for monitoring treatment response objectively.
| Diagnostic Test | What It Measures | Clinical Significance |
| TBUT (tear break-up time) | Tear film stability | Under 10 seconds is abnormal |
| Schirmer’s test | Aqueous tear production | Under 10 mm in 5 min is reduced |
| Corneal fluorescein staining | Epithelial surface damage | Confirms active disease severity |
| Meibography | Meibomian gland structure and dropout | Guides long-term prognosis |
| Tear osmolarity | Tear salt concentration | Over 308 mOsm/L confirms DED |
| OSDI score | Symptom burden | Tracks treatment response over time |
Treatment: A Layered Approach
Dry eye treatment is not one-size-fits-all. It is matched to disease type, severity, and the dominant mechanism driving symptoms.
Step 1: Environmental and Behavioural Changes
Reduce screen time or use the 20-20-20 rule — every 20 minutes, look at something 20 feet away for 20 seconds. Increase blink frequency consciously. Use a humidifier in air-conditioned environments. Wear wraparound glasses in wind and dry air.
Step 2: Lid Hygiene and Warm Compresses
Warm compresses applied for 10 minutes daily soften meibomian secretions and improve gland expressibility. Lid massage after warming clears blocked glands. Lid scrubs with baby shampoo or commercially prepared wipes reduce bacterial load on the lid margin.
Consistency matters more than intensity. Daily lid hygiene over months produces measurable improvement in tear film quality.
Step 3: Lubricating Eye Drops
Not all lubricants are equivalent. Drops containing carboxymethylcellulose, sodium hyaluronate, or polyethylene glycol provide longer contact time. Preservative-free formulations are essential for patients using drops more than four times daily — preservatives accelerate the surface damage they are meant to relieve.
Gel formulations and ointments provide longer relief but blur vision temporarily and are best used at night.
Step 4: Omega-3 Fatty Acid Supplementation
Omega-3 supplements — particularly EPA and DHA from fish oil or re-esterified triglyceride formulations — improve meibomian secretion quality and reduce ocular surface inflammation. The DREAM study showed that high-dose omega-3 did not significantly outperform olive oil placebo, but clinical practice and other evidence support a role for supplementation in evaporative dry eye.
A daily dose of 2000 to 3000 mg EPA+DHA for at least three months is typically recommended.
Step 5: Anti-Inflammatory Therapy
When inflammation is driving symptoms, lubricants alone are insufficient. Cyclosporine eye drops (0.05% or 0.1%) reduce T-cell mediated inflammation on the ocular surface and restore goblet cell density over three to six months of use. They are not a quick fix — patients must be counselled on the time course.
Lifitegrast 5% is an integrin antagonist that blocks the LFA-1 to ICAM-1 interaction driving ocular surface inflammation. It offers symptom relief somewhat faster than cyclosporine.
Short-term topical corticosteroids are used to rapidly break the inflammatory cycle, particularly at disease onset or during flares. They are not for long-term use.
Step 6: Procedural Treatments
Intense Pulsed Light (IPL) therapy targets abnormal blood vessels on the lid margin that drive meibomian gland inflammation. It also applies heat that melts obstructed meibum. Multiple sessions spaced three to four weeks apart produce sustained improvement in many patients with moderate to severe MGD.
Thermal pulsation devices (LipiFlow) deliver controlled heat and pressure to the inner eyelid to express inspissated meibum. The effect can last six to twelve months and is repeatable.
Punctal plugs block the drainage of tears from the ocular surface. They are appropriate for aqueous deficient dry eye when lubrication alone is inadequate. Dissolvable collagen plugs are trialled before permanent silicone plugs are inserted.
| Treatment | Best For | Time to Effect |
| Preservative-free lubricants | All types, daily use | Immediate symptom relief |
| Lid hygiene + warm compresses | Evaporative / MGD | 4 to 8 weeks of daily use |
| Omega-3 supplementation | Evaporative / MGD | 8 to 12 weeks |
| Cyclosporine drops | Inflammatory DED | 3 to 6 months |
| Lifitegrast drops | Inflammatory DED | 2 to 4 weeks for symptoms |
| IPL therapy | Moderate to severe MGD | After 3 to 4 sessions |
| Punctal plugs | Aqueous deficient DED | Days to weeks |
Monitoring Dry Eye Over Time
Dry eye is managed, not cured. Follow-up visits every three to six months allow the specialist to assess treatment response, adjust the regimen, and monitor for corneal surface deterioration.
Objective tests — TBUT, osmolarity, staining scores — are more reliable than symptoms alone. Patients often adapt to chronic discomfort and underreport severity. Imaging guides clinical decisions even when symptoms appear stable.
Meibomian gland dropout is irreversible. Preventing further loss is the priority once significant atrophy is identified.
Dry Eye and Systemic Disease
Dry eye is frequently a signal of systemic disease. Sjogren’s syndrome, rheumatoid arthritis, lupus, thyroid eye disease, and graft-versus-host disease all affect the ocular surface. Patients with unexplained severe dry eye — particularly younger women — should be evaluated for autoimmune conditions.
Conversely, patients already diagnosed with these conditions should have formal ocular surface assessments. Dry eye in this context needs co-management with the treating physician.
When to See a Glaucoma and Ocular Surface Specialist
Many patients with dry eye also have glaucoma or glaucoma suspect status. Glaucoma drops — particularly those with preservatives — are a significant cause of ocular surface disease. The benzalkonium chloride (BAK) in most preserved glaucoma drops is toxic to goblet cells and the corneal epithelium.
If you use glaucoma drops and have dry eye symptoms, your specialist needs to review both conditions together. Switching to preservative-free formulations or fixed-combination drops can reduce surface toxicity without compromising IOP control.
A specialist with expertise in both conditions can optimise your glaucoma management while actively protecting the ocular surface.
Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.
Frequently Asked Questions
Can dry eye disease be cured?
There is no permanent cure for most forms of dry eye disease. However, it can be very well controlled with the right treatment strategy. Many patients achieve significant symptom relief and stable ocular surface health with long-term management.
Are lubricating drops enough to treat dry eye?
For mild disease, lubricants provide adequate relief. For moderate to severe dry eye — or evaporative disease driven by meibomian gland dysfunction — drops manage symptoms but do not address the underlying cause. Lid hygiene, anti-inflammatory therapy, and sometimes procedural treatment are needed.
How do I know if my dry eye is getting worse?
Worsening symptoms, increased frequency of drop use, morning grittiness, light sensitivity, and fluctuating vision are all signs of progression. Objective worsening on TBUT, staining, or osmolarity testing confirms it. Do not wait for significant discomfort before seeking review.
Can diet help with dry eye?
Yes. Omega-3 fatty acids from oily fish, flaxseed, and walnuts support meibomian gland secretion quality. Adequate hydration matters. Foods high in omega-6 fatty acids and processed vegetable oils may worsen inflammation. A Mediterranean-style diet is broadly supportive of ocular surface health.
Is dry eye related to screen use?
Yes. Screen use reduces spontaneous blink rate from a normal 15 to 17 blinks per minute to as few as 3 to 5 blinks per minute. Reduced blinking causes tear film instability and accelerates evaporation. Deliberate blinking exercises and regular screen breaks are first-line recommendations for screen-related dry eye.
Can I wear contact lenses if I have dry eye?
Some patients with well-managed mild dry eye can wear contacts with modifications — daily disposable lenses, lubricating drops compatible with contact wear, and reduced wearing time. Patients with moderate to severe dry eye are advised to avoid contact lenses until surface health is restored. Scleral lenses are a specialist option for severe cases.
Does menopause cause dry eye?
Yes. Oestrogen and androgen deficiency after menopause reduces both aqueous and meibomian secretion. Dry eye prevalence in post-menopausal women is significantly higher than in age-matched men. Hormone replacement therapy has a complex relationship with dry eye — some studies show benefit, others do not. Ocular surface assessment after menopause is advisable.
Book a Dry Eye Assessment in Gurgaon
Dry eye responds best to early, structured management. A thorough ocular surface assessment — including meibography, osmolarity, and staining — identifies the cause and guides a treatment plan that works long-term.
If you are using lubricating drops daily and still struggling, the underlying mechanism has not yet been addressed. A specialist review changes that.
About the Author
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine. This article was updated in May 2026.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
Access her work on Pubmed, Google Scholar, ResearchGate and ORCID.
Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care
www.drshibalbhartiya.com
+91 88826 38735
1500+ Five Star Patient Reviews Google Business Profile
Upload your reports for a structured review.
If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation
Read More
Why Do Women Get Dry Eye More Often?
Dry Eyes: Tips to Soothe Sore Eyes
Why Dry Eye Is Worse in Air Conditioning and on Flights
Why Vision Becomes Blurred After Reading or Screen Use
Why Your Eyes Water Constantly
